Trend Toward Survival Benefit Seen for REM-Inhibition in ALS

Follow Drugslib on

Medically reviewed by Carmen Pope, BPharm. Last updated on May 22, 2025.

By Elana Gotkine HealthDay Reporter

THURSDAY, May 22, 2025 -- For patients with amyotrophic lateral sclerosis (ALS), rapid eye movement (REM) inhibition via receipt of antidepressant medication is associated with a trend toward survival benefit, according to a study presented at the American Thoracic Society 2025 International Conference, held from May 18 to 21 in San Francisco.

Cosmo Fowler, M.D., from the Emory University School of Medicine in Atlanta, and colleagues queried the TriNetX research network to examine whether pharmacological suppression of REM sleep can improve sleep disordered breathing and nocturnal hypoxemia in ALS. Data were included for 17,444 patients with ALS who had been prescribed riluzole; 14.3 percent comprised the REM-inhibited cohort (patients were prescribed one of several antidepressant medications associated with the suppression of REM sleep in the three years preceding inclusion criteria) and 2.1 percent comprised the non-REM-inhibited cohort (patients received antidepressants not linked to REM suppression). Patients who received prescriptions from both classes were excluded.

The researchers found that prior to propensity-score matching using age, race, and gender, the REM-inhibited group had significantly higher two-year Kaplan-Meier survival (47.18 versus 41.06 percent), with a hazard ratio of 1.21 (95 percent confidence interval, 1.022 to 1.433). After matching, the survival benefit trend persisted but did not reach significance (48.13 versus 41.06 percent; hazard ratio, 1.23; 95 percent confidence interval, 0.981 to 1.547). A consistent treatment effect was suggested by preserved proportionality throughout follow-up.

"While our investigation was limited by its retrospective nature and potential confounding factors inherent to electronic health record data, the results suggest that pharmacologically targeting a period of known vulnerability in ALS may have meaningful clinical impact," the authors write.

Abstract

More Information

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

Source: HealthDay

Posted : 2025-05-23 06:00

Read more

Disclaimer

Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.

The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.

Popular Keywords